SCHEMBL4335666

SCHEMBL4335666

Cc1cc(-c2noc(N)c2-c2ccncc2)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.59
MLYCD O95822 4/20 0.51
HSP90AA1 P07900 1/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPK9 P45984 2/20 0.42
MAPK10 P53779 2/20 0.42
MAPK11 Q15759 1/20 0.42
PTGS1 P23219 2/20 0.41
CSNK1D P48730 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PTGS2 P35354 1/20 0.39
TDO2 P48775 2/20 0.39
BRD4 O60885 1/20 0.39
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346446 0.89 MAPK14 (0.62) MAPK14MLYCDHSP90AA1NPC1RAB9A
SCHEMBL4340388 0.88 MAPK14 (0.66) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4337126 0.85 MAPK14 (0.66) MAPK14MLYCDNPC1RAB9AMAPK9
SCHEMBL1878582 0.84 MAPK14 (0.63) MAPK14MLYCDHSP90AA1NPC1RAB9A
SCHEMBL4346693 0.83 MAPK14 (0.56) MAPK14MLYCDHSP90AA1NPC1RAB9A
SCHEMBL27744883 0.83 MAPK14 (0.56) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4329365 0.82 MAPK14 (0.66) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4329246 0.82 MAPK14 (0.66) MAPK14MLYCDHSP90AA1NPC1RAB9A
SCHEMBL4341533 0.81 MAPK14 (0.72) MAPK14MLYCDNPC1RAB9AMAPK9
SCHEMBL4336972 0.81 MAPK14 (0.63) MAPK14MLYCDHSP90AA1RAB9AMAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036905-B1 PYRIDYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2012-12-12 EP disclosed
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885MLYCD 4475/4885HSP90AA1 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.